Exemestane

Product Details – Exemestane

Exemestane is a synthetic steroidal compound classified as an aromatase inhibitor. Structurally, it is derived from the androstenedione backbone, allowing it to interact with enzymes involved in estrogen biosynthesis. Within controlled research environments, it is primarily examined for its role in modulating enzymatic pathways responsible for the conversion of androgens into estrogens.

Due to its structural similarity to natural substrates, exemestane is often utilized in studies focusing on enzyme-substrate recognition, catalytic inactivation, and steroidal pathway regulation.

Mechanism of Action

Exemestane functions through irreversible inhibition of the aromatase enzyme (CYP19A1). It binds to the enzyme’s active site and forms a covalent interaction, resulting in permanent inactivation of enzymatic activity. This type of inhibition is commonly referred to as mechanism-based or “suicide” inhibition.

By inactivating aromatase, the compound suppresses the enzymatic conversion of androgenic substrates, such as testosterone and androstenedione, into estrogenic compounds. This leads to a measurable shift in the balance of steroidal metabolites at the biochemical level.

Additionally, exemestane demonstrates a high degree of selectivity for aromatase, with minimal interaction observed across other enzymes involved in steroidogenesis. This selectivity supports its use in studies analyzing targeted enzyme inhibition and pathway-specific modulation within steroid biosynthesis networks.

Chemical Properties of Exemestane

Research Applications

Aromatase Inhibition Studies

Exemestane is widely utilized in experimental models investigating aromatase (CYP19A1) activity. Its irreversible binding allows for detailed analysis of enzyme inactivation, catalytic suppression, and long-term effects on enzymatic turnover.

Steroidogenesis Pathway Research

The compound supports studies focused on steroid biosynthesis pathways by modulating the conversion of androgenic substrates into estrogenic metabolites. This enables examination of pathway regulation, substrate competition, and metabolic flux within endocrine-related systems.

Enzyme Selectivity Analysis

Due to its targeted interaction with aromatase, exemestane is applied in research comparing enzyme specificity across the cytochrome P450 family. This includes investigations into structural binding affinity, isoenzyme differentiation, and selective inhibition mechanisms.

Covalent Binding Mechanism Studies

Exemestane serves as a reference compound in studies exploring covalent enzyme inhibition. Its ability to form stable enzyme-inhibitor complexes allows researchers to examine irreversible binding kinetics and long-term enzyme deactivation processes.

Why Choose BehemothLabz to Buy Pancragen for Research

BehemothLabz supplies research-grade Pancragen produced under controlled laboratory conditions with strict quality assurance protocols in place. Each batch undergoes detailed analytical verification to ensure consistency in molecular composition and purity.

In addition, comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility across experimental applications. BehemothLabz maintains a compliance-focused approach, ensuring that all compounds are supplied exclusively for laboratory-based investigation and analytical research.

Disclaimer

Pancragen is intended strictly for laboratory research and analytical purposes only. It is not designed for diagnostic procedures, therapeutic applications, or any form of in vivo study.

All references to biochemical pathways, receptor interactions, and enzymatic processes are provided solely within a research context. This compound must be handled only by qualified professionals within controlled laboratory environments, in accordance with applicable regulations and safety standards.

Any use outside of these defined research conditions is strictly prohibited.

References

• Yardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., 3rd, Baselga, J., Gnant, M., Hortobagyi, G. N., Campone, M., Pistilli, B., Piccart, M., Melichar, B., Petrakova, K., Arena, F. P., Erdkamp, F., Harb, W. A., Feng, W., Cahana, A., Taran, T., Lebwohl, D., & Rugo, H. S. (2013). Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Advances in therapy, 30(10), 870–884. https://doi.org/10.1007/s12325-013-0060-1
• Turner, N. C., Swift, C., Kilburn, L., Fribbens, C., Beaney, M., Garcia-Murillas, I., Budzar, A. U., Robertson, J. F. R., Gradishar, W., Piccart, M., Schiavon, G., Bliss, J. M., Dowsett, M., Johnston, S. R. D., & Chia, S. K. (2020). ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(19), 5172–5177. https://doi.org/10.1158/1078-0432.CCR-20-0224